2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172680
    DSPE-PEG1000-VIP
    DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery.
    DSPE-PEG1000-VIP
  • HY-172681
    DSPE-PEG2000-VIP
    DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery.
    DSPE-PEG2000-VIP
  • HY-172682
    DSPE-PEG5000-VIP
    DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery.
    DSPE-PEG5000-VIP
  • HY-172695
    DSPE-PEG1000-WYRGRL
    DSPE-PEG1000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG1000-WYRGRL can be used for drug delivery.
    DSPE-PEG1000-WYRGRL
  • HY-172696
    DSPE-PEG2000-WYRGRL
    DSPE-PEG2000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG2000-WYRGRL can be used for drug delivery.
    DSPE-PEG2000-WYRGRL
  • HY-172697
    DSPE-PEG5000-WYRGRL
    DSPE-PEG5000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG5000-WYRGRL can be used for drug delivery.
    DSPE-PEG5000-WYRGRL
  • HY-172774
    TRPV1 antagonist 10 896584-55-7
    TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist (IC50 = 33.06 nM), moderate to weak URAT1 (IC50 = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor. TRPV1 antagonist 10 has analgesic and urate-lowering effect. TRPV1 antagonist 10 can be studied for research in hyperuricemia and inflammatory pain.
    TRPV1 antagonist 10
  • HY-172776
    Phosphodiesterase-IN-3 3042880-01-0
    Phosphodiesterase-IN-3 (Example 20) is a phosphodiesterase 4B inhibitor, with IC50s of <10 nM and 10-100 nM for PDE4B1 and PDE4D3, respectively. Phosphodiesterase-IN-3 has the potential for the research of idiopathic pulmonary fibrosis.
    Phosphodiesterase-IN-3
  • HY-172778
    HNW005
    HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1). It has a KD value of 204.6 nM and an IC50 of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC50 of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis.
    HNW005
  • HY-172781
    HDAC6-IN-55
    HDAC6-IN-55 (Compound 15B) is a potent HDAC6 inhibitor and an effective anti-inflammatory agent. HDAC6-IN-55 alleviates atopic dermatitis through anti-inflammatory effects facilitated via TLR4/MAPK, STAT3 and NF-κB pathways. HDAC6-IN-55 alleviates symptoms such as skin edema, dryness, crusting, and peeling in 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis mice.
    HDAC6-IN-55
  • HY-172782
    BuChE-IN-20
    BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC50 = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease.
    BuChE-IN-20
  • HY-172788
    NLRP3-IN-78 477546-27-3
    NLRP3-IN-78 (compound 21) is a NLRP3 inhibitor with the inhibition rate of 46.72% in GSDMD-induced pyroptosis at 5 μM. NLRP3-IN-78 binds to the NLRP3 protein and inhibits GSDMD-NT oligomerization. NLRP3-IN-78 also inhibits GSDMD cleavage, and upstream NF-κB signaling, demonstrating its anti-inflammatory activity.
    NLRP3-IN-78
  • HY-172790
    Cbz-(S,S)-Pro-Pro-allyl
    Cbz-(S,S)-Pro-Pro-allyl (compound 1a) is a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase with IC50 values of 0.146 nM, 0.003 nM, 0.64 nM for COX-1, COX-2, 5-LOX, respectively. Cbz-(S,S)-Pro-Pro-allyl has anti-inflammatory activity.
    Cbz-(S,S)-Pro-Pro-allyl
  • HY-172797
    DDR Inhibitor 2
    DDR Inhibitor 2 (compound 5a) is a discoidin domain receptor (DDR) inhibitor with an IC50 of 0.125 μM. DDR Inhibitor 2 can be used for study of fibrotic diseases.
    DDR Inhibitor 2
  • HY-172803
    Ferroptosis inducer-7 2723569-00-2
    Ferroptosis inducer-7 is an orally active and selective ferroptosis inducer via inositol 1,4,5-trisphosphate receptor (IP3R)/calcium release-activated calcium channel protein (ORAI). Ferroptosis inducer-7 exhibits a notable effect in alleviating anemia symptoms, suppressing bone marrow CTLs activation, and improving hematopoietic function in immune-mediated bone marrow failure. Ferroptosis inducer-7 can be studied in research for aplastic anemia.
    Ferroptosis inducer-7
  • HY-172806
    PARP14 inhibitor 1 3035493-13-8
    PARP14 inhibitor 1 (compound Q22) is a selective PARP14 inhibitor with an IC50 of 5.52 nM. PARP14 inhibitor 1 also exhibits anti-inflammatory effects and a half life of 182 min in mouse liver microsomes. PARP14 inhibitor 1 can be utilized in atopic dermatitis research.
    PARP14 inhibitor 1
  • HY-172809
    LSD1-IN-42
    LSD1-IN-42 (Compound 7ae) is an orally active LSD1 inhibitor that potently inhibits LSD1 activity (IC50 = 0.08 μM). LSD1-IN-42 downregulates PD-L1 expression and enhances T cell-mediated tumor killing effects. LSD1-IN-42 demonstrates significant anti-gastric cancer activity by inhibiting tumor cell invasion and migration.
    LSD1-IN-42
  • HY-172870
    PDE4B-IN-4
    PDE4B-IN-4 is a PDE4B (IC50: 2.82 nM) and TNF-α (IC50: 7.20 nM) inhibitor. PDE4B-IN-4 inhibits neutrophilia in a mouse lipopolysaccharide (LPS)-induced sepsis model and exhibits anti-inflammatory activity.
    PDE4B-IN-4
  • HY-172871
    Anti-inflammatory agent 102 3053104-47-2
    Anti-inflammatory agent 102 (Compound 11a) is an orally active anti-inflammatory agent. Anti-inflammatory agent 102 exerts its anti-inflammatory effect by blocking the activation of the ASK1/p38 MAPKs/NF-κB signaling pathway. Anti-inflammatory agent 102 has significant anti-inflammatory activity and can inhibit the release of NO, ROS, and inflammatory factors (such as IL-6, TNF-α, IL-1β). Anti-inflammatory agent 102 can be used in the study of inflammatory diseases such as ulcerative colitis (UC).
    Anti-inflammatory agent 102
  • HY-172875
    HPK1-IN-58
    HPK1-IN-58 is an inhibitor of HPK1 (IC50: 2.6 nM) and SLP76 (IC50: 20 nM). HPK1-IN-58 enhances IL-2 secretion and reverses PGE2-induced immunosuppression. HPK1-IN-58 can be used in anti-tumor immunity research.
    HPK1-IN-58
Cat. No. Product Name / Synonyms Application Reactivity